Drug Class Description
Antihistamines / non-opioid analgesics.

Generic Name
Buclizine hydrochloride, paracetamol

Drug Description
Migraleve Ultra, 50mg, tabletsGalpharm Migraine Recovery, 50mg, tablets.

Presentation
Film-coated tablet.Peach, oblong shaped cores debossed “5” and “0” on one side and scoreline on each side.

Indications
Migraleve Ultra are indicated for the acute relief of migraine attacks, with or without aura. Migraleve Ultra should only be used where there is a clear diagnosis of migraine.

Adult Dosage
The recommended dose is a single 50 mg tablet that should be swallowed whole with water. It is advisable that Migraleve Ultra be taken as soon as possible after the onset of a migraine attack although it is effective at whatever stage of the attack it is taken.If there is a response to the first tablet but the symptoms recur, a second tablet may be taken. However, this must be at least 2 hours after the first tablet. No more than two 50 mg tablets (total dose 100 mg) may be taken in any 24 hour period.If there is no response to the first tablet, a second tablet should not be taken for the same attack.

Child Dosage
Not to be used in children or adolescents under 18 years of age.The safety and effectiveness of Migraleve Ultra in children have not been established

Elderly Dosage
Not to be used in those over 65 years of age.Experience of the use of Migraleve Ultra in patients over 65 years is limited.

Contra Indications
Migraleve Ultra must not be used prophylactically.Hypersensitivity to any component of the preparation or to sulphonamides.Previous myocardial infarction, or those who have ischaemic heart disease, coronary vasospasm (Prinzmetal's angina), cardiac arrhythmias, peripheral vascular disease or symptoms or signs consistent with ischaemic heart disease.History of cerebrovascular accident (stroke) or transient ischaemic attack (TIA/mini-stroke).Known hypertension.Hepatic or renal impairment.History of seizures or other risk factors which lower the seizure threshold.Concurrent treatment with the following medications is contra-indicated:Ergotamine or derivatives of ergotamine (including methysergide).Monoamine oxidase inhibitors (MAOIs). Migraleve Ultra must not be used within 2 weeks of discontinuation of therapy with MAOIs.Any 5-HT1 receptor agonist (triptan).Migraleve Ultra is not to be used to treat the following rare variants of migraine:Hemiplegic migraine - migraine with aura including unilateral motor weakness.Basilar migraine - migraine with aura symptoms originating from the brain stem and/or both hemispheres such as double vision, difficulty in articulating words, clumsy and unco-ordinated movements, tinnitus, reduced level of consciousness.Ophthalmoplegic migraine – migraine headache with involvement of one or more ocular cranial nerves resulting in weakness of the muscles controlling eye movement.

Special Precautions
Migraleve Ultra should only be used where a clear diagnosis of migraine has been made by a doctor or a pharmacist. For pharmacy supply, patients should have an established pattern of migraine (a history of five or more migraine attacks occurring over a period of at least 1 year).Migraleve Ultra should not be taken concomitantly with other migraine therapies containing any triptan, ergotamine or derivative of ergotamine.If a migraineur fails to respond to the first tablet of Migraleve Ultra, the attack may be treated with simple analgesics. Further, the diagnosis of migraine should be reconsidered with a doctor.The recommended dose of Migraleve Ultra should not be exceeded.Migraineurs whose typical headaches persist for longer than 24 hours should seek advice from their doctor.Migraineurs in whom the pattern of symptoms has changed, or whose attacks have become more frequent, more persistent, or more severe, or who do not recover completely between attacks, should seek advice from their doctor.Anyone with atypical symptoms which include, but are not limited to, unilateral motor weakness, double vision, clumsy and unco-ordinated movements, tinnitus, reduced level of consciousness, seizure-like movements, or recent onset of rash with headache should seek advice from their doctor.Patients whose migraine symptoms appear for the first time after age 50 should seek advice from their doctor as there may be a more serious underlying cause.Migraineurs who experience four or more migraine attacks per month should be referred to a doctor for ongoing management.It should be noted that migraineurs may be at risk of certain cerebrovascular events (e.g. cerebrovascular accident, transient ischaemic attack).Following administration, sumatriptan can be associated with transient symptoms including chest pain and tightness that may be intense and involve the throat (see Section 4.8, Undesirable effects). Typically, such symptoms develop within 30 minutes of treatment and last for less than 2 hours. Where such symptoms are thought to indicate ischaemic heart disease, medical eva luation should be obtained immediately and no further doses of Migraleve Ultra should be taken until considered appropriate by a doctor.Migraleve Ultra should not be used by migraineurs in whom unrecognised cardiac disease is likely without a prior risk assessment by a doctor or pharmacist. Special consideration should be given to postmenopausal women and men over 40. Risk factors for heart disease include hypercholesterolaemia, regular smoking, marked obesity, diabetes or a family history of early heart disease (father/brother developed heart disease before the age of 55, mother/sister developed heart disease before the age of 65). Anyone who has three or more of these risk factors is not suitable for pharmacy supply of sumatriptan. These eva luations may not identify everyone who has cardiac disease and, in very rare cases, serious cardiac events have occurred without underlying cardiovascular disease.There have been rare postmarketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. Serotonin syndrome has been reported following concomitant treatment with triptans and serotonin noradrenaline reuptake inhibitors (SNRIs). If concomitant treatment with Sumatriptan and an SSRI/SNRI is clinically warranted, appropriate observation of the patient is advised.Undesirable effects may be more common during concomitant use of triptans and herbal preparations containing St John's wort (Hypericum perforatum).Patients with known hypersensitivity to sulphonamides may exhibit an allergic reaction following administration of sumatriptan. Reactions may range from cutaneous hypersensitivity to anaphylaxis. Although evidence of cross-sensitivity is limited, treatment with Migraleve Ultra is contraindicated in these patients.Women with migraine who are taking the combined oral contraceptive have an increased risk of stroke and should seek advice from their doctor if migraine attacks started recently (within the last 3 months), migraine symptoms have worsened or they have migraine with aura.Prolonged use of any type of painkiller for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained and treatment should be discontinued. The diagnosis of medication overuse headache (MOH) should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of headache medications.Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Interactions
Studies in healthy subjects show that sumatriptan does not interact with propranolol, flunarizine, pizotifen or alcohol.Sumatriptan has the potential to interact with MAOIs, ergotamine and derivatives of ergotamine. The increased risk of coronary vasospasm is a theoretical possibility and therefore concomitant administration with MAOIs and ergotamines is contra-indicated.Prolonged vasospastic reactions have been reported with ergotamine. As these effects may be additive, 24 hours should elapse before sumatriptan can be taken following any ergotamine-containing preparation. Conversely, ergotamine-containing preparations should not be taken until 6 hours have elapsed following sumatriptan administration.Rarely, an interaction may occur between sumatriptan and SSRIs. There is a risk of pharmacodynamic interaction between sumatriptan and tricyclic antidepressants.There have been rare post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the use of SSRIs and Sumatriptan. Serotonin syndrome has also been reported following concomitant treatment with triptans and SNRIs.Undesirable effects may be more common during concomitant use of triptans and herbal preparations containing St John's wort (Hypericum perforatum).

Adverse Reactions
Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/10,000, <1/1000) and very rare (<1/10,000) including isolated reports.Immune System DisordersVery rare: Hypersensitivity reactions ranging from cutaneous hypersensitivity (such as urticaria) to anaphylaxis.Nervous System DisordersCommon: Tingling, dizziness, drowsiness.Very rare: Seizures, although some have occurred in patients with either a history of seizures or concurrent conditions predisposing to seizures there are also reports in patients where no such predisposing factors are apparent.Nystagmus, scotoma.Eye DisordersVery rare: Flickering, diplopia, reduced vision. Loss of vision (usually transient). However, visual disorders may also occur during a migraine attack itself.Cardiac DisordersVery rare: Bradycardia, tachycardia, palpitations, cardiac arrhythmias, transient ischaemic ECG changes, coronary artery vasospasm, myocardial infarction (see Contraindications, Special Warnings and special precautions for use).Vascular DisordersCommon: Transient increases in blood pressure arising soon after treatment. Flushing.Very rare: Hypotension, Raynaud's phenomenon.Gastrointestinal DisordersCommon: Nausea and vomiting occurred in some patients but it is unclear if this is related to Sumatriptan or the underlying condition.Very rare: Ischaemic colitis.Not known: Diarrhoea.Musculoskeletal and Connective Tissue DisordersThe following symptom is usually transient and may be intense and can affect any part of the body including the chest and throat:Common: Sensations of heaviness.Very rare: Neck stiffness.Not known: Arthralgia.Psychiatric disordersNot known: Anxiety.Skin and subcutaneous tissue disordersNot known: Hyperhidrosis.General Disorders and Administration Site ConditionsThe following symptoms are usually transient and may be intense and can affect any part of the body including the chest and throat:Common: Pain, sensations of heat, pressure or tightness.The following symptoms are mostly mild to moderate in intensity and transient:Common: Feelings of weakness, fatigue.InvestigationsVery rare: Minor disturbances in liver function tests have occasionally been observed.

Manufacturer
Pfizer Consumer

Drug Availability
(POM)

Updated
11 May 2010